A detailed history of Cornerstone Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cornerstone Advisors, LLC holds 13,000 shares of VRTX stock, worth $6.04 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
13,000
Previous 12,200 6.56%
Holding current value
$6.04 Million
Previous $5.72 Million 5.74%
% of portfolio
0.24%
Previous 0.23%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$460.0 - $505.78 $368,000 - $404,624
800 Added 6.56%
13,000 $6.05 Million
Q2 2024

Aug 09, 2024

SELL
$392.81 - $485.53 $39,281 - $48,553
-100 Reduced 0.81%
12,200 $5.72 Million
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $1.65 Million - $1.97 Million
-4,800 Reduced 28.07%
12,300 $5 Million
Q3 2023

Nov 09, 2023

SELL
$338.18 - $362.46 $2.1 Million - $2.25 Million
-6,200 Reduced 26.61%
17,100 $5.95 Million
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $1.04 Million - $1.16 Million
3,300 Added 16.5%
23,300 $8.2 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $2 Million - $2.25 Million
-7,000 Reduced 25.93%
20,000 $5.78 Million
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $1.17 Million - $1.46 Million
5,000 Added 22.73%
27,000 $7.61 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $1.69 Million - $1.99 Million
9,000 Added 69.23%
22,000 $4.44 Million
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $1.45 Million - $1.69 Million
-7,000 Reduced 35.0%
13,000 $2.79 Million
Q2 2020

Aug 11, 2020

BUY
$225.48 - $295.8 $1.58 Million - $2.07 Million
7,000 Added 53.85%
20,000 $5.81 Million
Q1 2020

May 13, 2020

BUY
$199.77 - $247.81 $2.6 Million - $3.22 Million
13,000 New
13,000 $3.09 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cornerstone Advisors, LLC Portfolio

Follow Cornerstone Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornerstone Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cornerstone Advisors, LLC with notifications on news.